newsfilter
← Latest News
GlobeNewswire·

Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 8, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule